MONMOUTH JUNCTION, NJ--(Marketwire - November 15, 2007) - MedaSorb Technologies Corporation (OTCBB: MSBT) (FRANKFURT: HQE.F), a medical device company focused on the development of its platform technology for removal of toxins from blood and physiologic fluids, announced today it has received an allowance for Patent Application 10/980510 entitled “Devices, Systems & Methods for Reducing Levels of Pro-Inflammatory or Anti-Inflammatory Stimulators or Mediators in the Blood Generated as a result of Extracorporeal Blood Processing.”
